详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma

96| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Radiation Oncology, Peking University Cancer Hospital, Beijing, China [2]Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China [3]Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu, China [4]Department of Radiation Oncology, Fujian Cancer Hospital, Fuzhou, China [5]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China [6]BeiGene (Beijing) Co., Ltd., Beijing, China

出处：

DOI：

ISSN：

关键词： concurrent chemoradiotherapy esophageal squamous cell carcinoma immune checkpoint inhibitor immunotherapy Phase III clinical trial programmed cell death-1 (PD-1) tislelizumab

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

最新[2023]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2021]版：

Q3 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY

影响因子： 3 最新[2023版] 2.9 最新五年平均 3.674 出版当年[2021版] 3.392 出版当年五年平均 3.404 出版前一年[2020版] 3.3 出版后一年[2022版]

第一作者：

第一作者机构： [1]Department of Radiation Oncology, Peking University Cancer Hospital, Beijing, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy [2]Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients [3]A phase III multicenter randomized clinical trial of 60 Gy vs 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma. [4]Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial [5]Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical trial [6]Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension [7]Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) [8]CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. [9]Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) [10]Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)